Oxidative metabolites of 5-S-cysteinyldopamine inhibit the α-ketoglutarate dehydrogenase complex: Possible relevance to the pathogenesis of Parkinson's disease

Journal of Neural Transmission

Volumn 107, Issue 8-9, 2000, Pages 959-978

  Shen, X M ^a   Li, H ^a   Dryhurst, G ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

ketoglutarate dehydrogenase; 5 S cysteinyldopamine; DHBT 1; Parkinson's disease

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; CATALASE; CYTOCHROME C OXIDASE; DOPAMINE DERIVATIVE; GLUTATHIONE; OXOGLUTARATE DEHYDROGENASE; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CATALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MITOCHONDRIAL MEMBRANE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMAL; ANTIOXIDANTS; BRAIN; CATALASE; CYTOCHROME-C OXIDASE; DOPAMINE; ENZYME INHIBITORS; INTRACELLULAR MEMBRANES; KETOGLUTARATE DEHYDROGENASE COMPLEX; MALE; MITOCHONDRIA; OXIDATION-REDUCTION; PARKINSON DISEASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; SUPPORT, U.S. GOV'T, P.H.S.; THIAZINES;

EID: 0033787328     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070045     Document Type: Article

References (67)

1. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat
2. Marked rise of cysteine levels in many regions of brain after administration of 2-oxothiazolidine-4-carboxylic acid
3. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
4. Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: Effect of pH and iron saturation
5. Regulation of α-ketoglutarate dehydrogenase cooperative properties in substrate binding by thiol-disulfide exchange
6. ATP-regulated neuronal catecholamine uptake: A new mechanism
7. +)
8. Rapid ATP loss caused by MPTP in mouse brain
9. + enhances potassium evoked striatal release through a Ω-conotoxin-insensitive, tetrodotoxin- and nimodipine-sensitive calcium dependent mechanism
10. Role of astrocytes in maintaining cerebral glutathione homeostasis and in protecting the brain against xenobiotics and oxidative stress
11. Mitochondrial dysfunction in neurodegeneration
12. α-Tocopherol levels in brain are not altered in Parkinson's disease
13. The γ-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture
14. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione
15. Ageing and Parkinson's disease: Substantia nigra regional selectivity
16. The inactivation of Fe-S cluster containing hydrolysases by superoxide
17. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the depigmentation of substantia nigra
18. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
19. Oxidation pathways for catcholamines in the genesis of neuromelanin and cytotoxic quinones
20. The anatomy and pigmentation of the human substantia nigra in relation to selective vulnerability
21. Exacerbation of NMDA, AMPA and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate
22. Inhibitors of mitochondrial respiration, iron (II) and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: Potential implications to Parkinson's disease
23. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections
24. Biochemical pathophysiology of Parkinson's disease
25. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
26. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications
27. Association between the gene encoding the E2 subunit of α-ketoglutarate dehydrogenase complex and Parkinson's disease
28. NMDA receptor-dependent superoxide production and neurotoxicity
29. The ageing liver; drug clearance and an oxygen diffusion barrier hypothesis
30. Brain α-ketoglutarate dehydrogenase complex: Kinetic properties, regional distribution, and effects of inhibitors
31. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease
32. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: Potential relevance to the pathogenesis of Parkinson's disease
33. Possible roles of neuromelanin in the pathogenesis of Parkinson's disease
34. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease
35. + toxicity in striatal dopaminergic terminals: Possible involvement of ascorbate
36. Parkinson's after exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate)
37. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes
38. Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion
39. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
40. An immuno-histochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease
41. Glutamate becomes neurotoxic when intracellular energy levels are reduced
42. Sulfhydryl drugs reduced neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse
43. Energy driven uptake of N-methyl-4-phenypyridine by brain mitochondria mediates the neurotoxicity of MPTP
44. Influence of metabolic inhibitors on mitochondrial permeability transition and glutathione status
45. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brain
46. +-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis
47. Histology: A text and atlas
48. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation
49. MPTP. A dopaminergic neurotoxin
50. Maintenance of neuronal glutathione by glial cells
51. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures
52. 1 reductase (complex I) deficiency in Parkinson's disease
53. 2+ permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production
54. Multiple roles of glutathione in the nervous system
55. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's disease
56. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia
57. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease. Possible mechanisms of formation involving reactive oxygen species
58. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies with mice
59. Origin and functional significance of the complex I deficit in Parkinson's disease
60. Cytochrome oxidase from beef heart mitochondria
61. Genes and parkinsonism
62. Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes
63. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment
64. Screening for thiol compounds: Depolarization-induced release of glutathione and cysteine from rat brain slices
65. Reactions of cysteine and cysteine derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: Potential insights into idiopathic Parkinson's disease